Trial Profile
Phase I, Double-Blind, Randomized, Three-Arm, Parallel-Group, Pharmacokinetic, Safety and Tolerability Study in Healthy Volunteers to Evaluate Bioequivalence of LusiNEX and Tocilizumab (EU and US)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Jan 2020
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Mycenax Biotech
- 25 Feb 2019 Status changed from active, no longer recruiting to completed.
- 24 Dec 2018 Primary endpoint has been met. (Pharmacokinetics- serum assay for area under concentration-time curve from time 0 (predose) extrapolated to infinity AUC(0-8)).), according to a Mycenax Biotech media release.
- 24 Dec 2018 Results presented in a Mycenax Biotech media release.